We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Morie Gertz

Morie A Gertz MD, MACP

Roland Seidler Jr. Professor, Department of Medicine, and Chair Emeritus, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota

Dr. Gertz is the Roland Seidler Jr. Professor of the Art of Medicine and Chair Emeritus of the Department of Internal Medicine, at Mayo Clinic in Rochester, Minnesota. He is a Master of the American College of Physicians. Undergraduate degree was awarded with highest distinction from Northwestern University graduating Phi Beta Kappa. Dr. Gertz received his medical degree cum laude from Loyola Medical School in Maywood, Illinois and was elected to Alpha Omega Alpha the medical honor society. He completed a 3-year medical residency at Rush Presbyterian St. Luke’s Hospital in Chicago, Illinois, and was voted Resident of the Year for 2 of those years. He completed training in hematology and oncology at the Mayo. He was awarded the Mayo Distinguished Clinician Award for his contributions to patient care. He was the first treasurer of the International Society of Amyloidosis and was the first treasurer of the International Myeloma Society. He has authored over 700 peer-reviewed publications and over 50 book chapters. He serves on the editorial boards of Amyloidosis, Acta Haematologica and Clinical Lymphoma and Myeloma. He is co-editor of Neoplastic Diseases of the Blood.

Disclosures

Dr. Gertz receives honorarium from Akcea, Alnylym and Caelum Pharmacuticals.

Recent Contributions to PracticeUpdate:

  1. Characteristics of Acquired Transthyretin Amyloidosis